Current Report · Items 5.03, 9.01 · 8-K

Compass Therapeutics, Inc.

CMPXNASDAQEQUITYCurrent

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Filed Jun 23, 2026Accepted Jun 22, 2026, 5:45 PM EDTCIK 1738021Accession 0001171843-26-004224

Company context

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts.

Current securities

CMPXNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 5.03, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.03Item 5.03 - Amendments to Articles/Bylaws

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 22, 2026, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the adoption of the Second Amended and Restated Bylaws of the Company, effective as of June 22, 2026 (the “New Bylaws”), which amend and restate the Amended and Restated Bylaws of the Company, dated as of July 17, 2020 (the “Existing Bylaws”), in their entirety. The New Bylaws amended the Existing Bylaws to establish exclusive jurisdiction in the United States District Courts for the District of Delaware and District of Massachusetts for resolving any action asserting a claim arising under Securities Act of 1933, as amended. The foregoing description of the New Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the New Bylaws, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.